Home › Funds › PFM Health Sciences, LP › ASND

PFM Health Sciences, LP position in ASND

ASCENDIS PHARMA A/S · Health Care

PFM Health Sciences, LP reported holding 233,171 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$62.2M, representing 5.45% of its reported portfolio and ranking #1 among its reported holdings. PFM Health Sciences, LP has disclosed ASND holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)233.17K sh
Reported value held$62.19M
Portfolio Weight5.45%
First reportedQ1 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How PFM Health Sciences, LP's ASND position evolved

PFM Health Sciences, LP first disclosed a stake in ASND in Q1 2024 at 6,000,000 shares (US$6.9M). The position peaked in Q2 2026 at 233,171 shares, worth US$62.2M. Across 10 filings, PFM Health Sciences, LP increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 233,171 shares valued at US$62.2M — an increase of 210,771 shares quarter over quarter.. Notable position changes include a 200% increase in Q2 2024 (shares rose 9% over the following quarter), a 43800% increase in Q1 2025 (shares rose 11% over the following quarter), a 941% increase in Q2 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 6.00M $6.93M New
Q2 2024 18.00M $20.10M Add
Q3 2024 90.77K $13.55M Reduce
Q4 2024 52.39K $7.21M Reduce
Q1 2025 23.00M $27.34M Add
Q2 2025 23.00M $28.84M Hold
Q3 2025 11.52M $15.70M Reduce
Q4 2025 10.65M $15.13M Reduce
Q1 2026 22.40K $5.12M Reduce
Q2 2026 233.17K $62.19M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 42 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has PFM Health Sciences, LP held ASND?

PFM Health Sciences, LP has disclosed ASND holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is PFM Health Sciences, LP's current position in ASND?

As of Q2 2026, PFM Health Sciences, LP holds 233.17K shares of ASND (ASCENDIS PHARMA A/S), valued at $62.19M, representing 5.45% of its reported portfolio and ranking #1.

Has PFM Health Sciences, LP been buying or selling ASND?

In the latest 13F filing (Q2 2026), PFM Health Sciences, LP increased its position in ASND. The position peaked in Q2 2026 at 233.17K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.